Practical Pharmacogenomic Approaches to Heart Failure Therapeutics

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current Treatment Options in Cardiovascular Medicine

• Publication date

  2016-08-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11936-016-0483-5PMID 27566707
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Pharmacogenetic Investigation of Intravenous Furosemide in Decompensated Heart Failure: A Meta-Analysis of 3 Clinical Trials

  2015cited by this paper
• Clinical and Genetic Factors Associated With Thiazide-Induced Hyponatremia

  2015cited by this paper
• Racial Differences in Heart Failure Outcomes: Evidence From the Tele-HF Trial (Telemonitoring to Improve Heart Failure Outcomes).

  2015cited by this paper
• Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure

  2015cited by this paper
• Genetic Factors Influencing B-type Natriuretic Peptide-Mediated Production of Cyclic Guanosine Monophosphate and Blood Pressure Effects in Heart Failure Patients

  2015cited by this paper
• Differences in the clinical characteristics of ethnic minority groups with heart failure managed in specialized heart failure clinics.

  2014cited by this paper
• G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.

  2014influential reference
• Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide.

  2014cited by this paper
• Race, common genetic variation, and therapeutic response disparities in heart failure.

  2014cited by this paper
• Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema

  2013cited by this paper
• Association of Genetic Variation with Gene Expression and Protein Abundance within the Natriuretic Peptide Pathway

  2013cited by this paper
• Racial/Ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure.

  2013cited by this paper
• Association between adrenergic receptor genotypes and beta‐blocker dose in heart failure patients: analysis from the HF‐ACTION DNA substudy

  2013cited by this paper
• Interaction of digitalis-like compounds with p-glycoprotein.

  2013cited by this paper
• β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity.

  2013cited by this paper
• Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner.

  2012cited by this paper
• Pharmacogenetics and healthcare outcomes in patients with chronic heart failure

  2012cited by this paper
• Pharmacogenetics of β-Blockers

  2012cited by this paper
• A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study

  2012cited by this paper
• Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project

  2012cited by this paper
• Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users

  2011cited by this paper
• The genetics of loop diuretic effects

  2010cited by this paper
• Role of Beta-Adrenergic Receptor Gene Polymorphisms in the Long-Term Effects of Beta-Blockade with Carvedilol in Patients with Chronic Heart Failure

  2010cited by this paper
• Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation.

  2010cited by this paper
• An &agr;2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the &bgr;-Blocker Bucindolol in Chronic Heart Failure

  2010cited by this paper
• Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol.

  2009cited by this paper
• Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.

  2008cited by this paper
• A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure

  2008cited by this paper
• Determinants of Steady-State Torasemide Pharmacokinetics

  2008cited by this paper
• Genetic polymorphism, medical therapy and sequential cardiac function in patients with heart failure.

  2008cited by this paper
• Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration

  2008cited by this paper
• Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure.

  2007cited by this paper
• Pharmacogenetics of beta-blockers.

  2007cited by this paper
• Genetic Variation in the Renal Sodium Transporters NKCC2, NCC, and ENaC in Relation to the Effects of Loop Diuretic Drugs

  2007cited by this paper
• Pharmacogenetics of β‐Blockers

  2007cited by this paper
• Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.

  2007influential reference
• Relation of β2-Adrenoceptor Haplotype to Risk of Death and Heart Transplantation in Patients With Heart Failure

  2007cited by this paper
• Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients.

  2007cited by this paper
• Synergistic polymorphisms of &bgr;1 and &agr;2C-adrenergic receptors and the influence on left ventricular ejection fraction response to &bgr;-blocker therapy in heart failure

  2007cited by this paper
• Effect of ABCB1 (MDR1) 3435C >T and 2677G >A,T polymorphisms and P-glycoprotein inhibitors on salivary digoxin secretion in congestive heart failure patients.

  2007cited by this paper
• Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial.

  2006cited by this paper
• A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure

  2006cited by this paper
• A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.

  2006influential reference
• Is there a role of the Thr164Ile-β2-adrenoceptor polymorphism for the outcome of chronic heart failure?

  2006cited by this paper
• Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.

  2005cited by this paper
• Ser49Gly of β1‐adrenergic receptor is associated with effective β‐blocker dose in dilated cardiomyopathy

  2005cited by this paper
• Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy.

  2005cited by this paper
• Sympathoneural and adrenomedullary functional effects of &agr;2C-adrenoreceptor gene polymorphism in healthy humans

  2005cited by this paper
• β2-Adrenergic Receptor Genotype and Survival AmongPatients Receiving β-Blocker Therapy After an Acute Coronary Syndrome

  2005cited by this paper
• Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure.

  2004cited by this paper
• Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy.

  2004cited by this paper
• Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.

  2004cited by this paper
• Association of β-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy

  2004cited by this paper
• Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

  2004cited by this paper
• An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study

  2003cited by this paper
• Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization.

  2003cited by this paper
• Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 β1‐adrenoceptors versus Gly389 β1‐adrenoceptors in isolated human atrial myocardium

  2003cited by this paper
• Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure.

  2003cited by this paper
• β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure

  2003influential reference
• Pathophysiology of congestive heart failure.

  2003cited by this paper
• The Myocardium-protective Gly-49 Variant of the β1-Adrenergic Receptor Exhibits Constitutive Activity and Increased Desensitization and Down-regulation*

  2002cited by this paper
• Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure.

  2002cited by this paper
• MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males.

  2002cited by this paper
• Synergistic Polymorphisms of β1- and α2C-Adrenergic Receptors and the Risk of Congestive Heart Failure

  2002cited by this paper
• Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.

  2001cited by this paper
• A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

  2001cited by this paper
• The human G-protein beta3 subunit C825T polymorphism is associated with coronary artery vasoconstriction.

  2001cited by this paper
• Pharmacogenetic Interactions Between &bgr;-Blocker Therapy and the Angiotensin-Converting Enzyme Deletion Polymorphism in Patients With Congestive Heart Failure

  2001cited by this paper
• The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization.

  2001cited by this paper
• A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE

  2001cited by this paper
• Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

  2000cited by this paper
• A Four Amino Acid Deletion Polymorphism in the Third Intracellular Loop of the Human α2C-Adrenergic Receptor Confers Impaired Coupling to Multiple Effectors*

  2000cited by this paper
• Angiotensin-converting enzyme gene polymorphism influences degree of left ventricular hypertrophy and its regression in patients undergoing operation for aortic stenosis.

  1999cited by this paper
• Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.

  1999cited by this paper
• Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy.

  1999cited by this paper
• A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor*

  1999cited by this paper
• Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission

  1999cited by this paper
• The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure.

  1998cited by this paper
• An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

  1990cited by this paper

• Association of PCSK9 Variants with the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy.

  2021cites this paper
• Short-Term Therapies for Treatment of Acute and Advanced Heart Failure—Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?

  2019cites this paper
• Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review

  2018cites this paper
• DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics

  2018cites this paper
• Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long‐term side effects

  2017cites this paper
• Big Data and Genome Editing Technology: A New Paradigm of Cardiovascular Genomics

  2017cites this paper
• Healthcare in the 21st century.

  2017cites this paper